Papers After 2000

1.Law P, Weinstein J, Ben Hain S et al. World's first human myoblast transfer into the heart. Frontiers in Physiology 2000; A85.

2.Law P, Weinstein J, Ben Hain S et al. World's first human myoblast transfer into the heart. Acta Physiol Scand 2000; A1-A114.

3.Law, P.K., Nuclear Transfer and Human Genome Therapy. Business Briefing: Future Drug Discovery Genomics: 38-42, December 2001.

4.Law PK, Haider Kh., Fang G et al. Mechanisms of myoblast transfer in treating heart failure (2002) In: Kimchi, A., Ed., Advances in Heart Failure, Medimont, 43-48.

5.Law, P.K., The Regenerative Heart. Business Briefing: PharmaTech 2002 Drug Discovery: 65-71, April 2002.

6.Law, P.K., Concomitant Angiogenesis/Myogenesis in the Regenerative Heart. Business Briefing: Future Drug Discovery, Genomics: 64-67, October 2002.

7.Haider Kh H., Ye L., Jiang SJ., Law PK and Sim EKW. Avoiding compliance with histocompatibility dogma using immune privileged cell xenografts. Ann Thorac Surg 2003; 76:339-40.

8.Sim EKW, Haider Kh H., and Law PK. Single fiber skeletal muscletransplantation or purified myoblast engraftment? J Thoracic Cardiovasc Surgery 2003;125:5.

9.Haider Kh H., Ye L., Jiang SJ., Law PK., Sim EKW. Myoblast transplantation for cardiac repair using transient immunosuppression. Basic Appl Myol 2003,13(1): 45-52.

10.Haider HKh. , Jiang S, Ye L, Law P K and Sim EKW. Human skeletal myoblasts: potential for improving outcome of patients with end-Stage heart failure. ASEAN Heart Journal 2003; 10:1.

11.Law, P. K., Fang, G., Chua, F., Kakuchaya, T., and Bockeria, L. A. (2003). First-in-Man myoblast allografts for heart degeneration. Int. J. Med. Implants Devices 1: 100 – 155.

12.Ye L, Haider KH, Jiang SJ, Ling LH, Niagara MI, Rufaihah AJ, Law PK, Sim EK. Angiomyogenesis using human myoblast carrying human VEGF165 for injured heart. Ann Acad Med Singapore. 2003, 32:S21-3.

13.Ye L, Haider HKh, Jiang S, Ge R, Law PK, Sim EK.High efficiency transduction of human VEGF165 into human skeletal myoblasts: in vitro studies. Exp Mol Med. 2003, 35:412-20.

14.Haider HKh, Lei Y, Jiang S, Law PK, Sim EK .Avoiding compliance with histocompatibility dogma using immune privileged cell xenografts. Ann Thorac Surg. 2003,76:339-40.

15.Sim EK, Haider HK, Law PK. Single fiber skeletal muscle transplantation or purified myoblast engraftment? J Thorac Cardiovasc Surg. 2003,125:1181-2.

16.Law PK, Haider K, Fang G, Jiang S, Chua F, Lim YT, Sim E. Human VEGF165-myoblasts produce concomitant angiogenesis/myogenesis in the regenerative heart. Mol Cell Biochem 2004, 263:173-8.

17.Law PK , Law DLM , Lu P, Guo J, Lu Y, Xue YF, and Li X. The world's first myoblast study of Type II diabetic patients。 Business Briefing: North American Pharmacotherapy 2004-Issue 2

18.Haider HKh, Ye L, Jiang S, Ge R, Law PK, Chua T, Wong P, Sim EK. Angiomyogenesis for cardiac repair using human myoblasts as carriers of human vascular endothelial growth factor. J Mol Med. 2004, 82:539-49.

19.Haider HKh, Jiang SJ, Ye L, Aziz S, Law PK, Sim EK. Effectiveness of transient immunosuppression using cyclosporine for xenomyoblast transplantation for cardiac repair. Transplant Proc. 2004, 36:232-5.

20.Haider Husnain Kh; Ye Lei; Jiang Shujia; Ge Ruowen; Law Peter K; Chua Terrance; Wong Phillip; Sim Eugene K W. Angiomyogenesis for cardiac repair using human myoblasts as carriers of human vascular endothelial growth factor. J Mol Med 2004;82:539-49.

21.Haider Husnain Kh; Ye Lei; Jiang Shujia; Law Peter K; Sim Eugene K W. Immunosuppression and xenotransplantation of cells for cardiac repair. The Ann Thorac Surg 2004;77(3):1133; author reply 1133-4.

22.Ye L, Haider HKh, Jiang S, Ling LH, Ge R, Law PK, Sim EK. Reversal of myocardial injury using genetically modulated human skeletal myoblasts in a rodent cryoinjured heart model. Eur J Heart Fail. 2005, 7:945-52.

23.Ye L, Haider HKh, Jiang S, Ge R, Law PK, Sim EK. In vitro functional assessment of human skeletal myoblasts after transduction with adenoviral bicistronic vector carrying human VEGF165 and angiopoietin-1. J Heart Lung Transplant. 2005, 24: 1393-402.

24.Sim Eugene K W; Haider Husnain K H; Aziz Salim; Ooi Oon C; Law Peter K. Myoblast transplantation on the beating heart. Internat Surg 2005;90:148-50.

25.Deng W, Ye Lei, Esa WB , Haider Kh H, Ratha M, Law PK, Lim YT, Teh M, Sim EKW. Liposome Mediated Gene Delivery System Using Human Skeletal Myoblasts.

Proceedings of the International Federation for Medical and Biological Engineering 2005; 12: 1B2-05.

26.Law PK, Law DL, Lu P, Sim EKW, Haider Kh H, Ye Lei, Li X, Vakhromeeva MN, Berishvili II, Bockeria LA, Liew CC. Human myoblast genome therapy. J Geriat Cardiol 2006; 3(3): 135-151.

27.Ye Lei, Haider Kh H, Jiang SJ, Tan RS, Song IC, Ge RW, Law PK, Sim EKW. Skeletal myoblast based delivery of angiogenic growth factors: a comparison between angiopoietin-1 and VEGF gene delivery for therapeutic angiogenesis in the heart. J Geriat Cardiol 2006; 3(3): 152-160.

28.Law, P.K.; Goodwin, T.G.; Fang, Q.; Chen, M.; Li, H.J.; Florendo, J.A.; Kirby, D.S. Myoblast transfer therapy for Duchenne muscular dystrophy. Pediatr Int 2007 ; 33:206-15.

29.Law P K, Law DM, Lu P. Anti-aging aesthetica (AAA): Beautiful and strong forever. www.njscrefcharm.org/ejournal/lawantiaging307.html, 2007.

30.Ye Lei; Haider Husnain Kh; Jiang Shujia; Tan Ru San; Ge Ruowen; Law Peter K; Sim Eugene K W. Improved angiogenic response in pig heart following ischaemic injury using human skeletal myoblast simultaneously expressing VEGF165 and angiopoietin-1. Eur J Heart Fail 2007;9: 15-22.

31.Ye Lei; Haider Husnain Kh; Tan RuSan; Toh WeeChi; Law Peter K; Tan WeeBeng; Su LiPing; Zhang Wei; Ge RuoWen; Zhang Yong; Lim YeanTeng; Sim Eugene K W. Transplantation of nanoparticle transfected skeletal myoblasts overexpressing vascular endothelial growth factor-165 for cardiac repair.Circulation 2007;116:I113-20.

32.Guo Changfa; Haider Husnain Kh; Shim Winston S N; Tan Ru-San; Ye Lei; Jiang Shujia; Law Peter K; Wong Philip; Sim Eugene K W. Myoblast-based cardiac repair: xenomyoblast versus allomyoblast transplantation. J Thorac Cardiovasc Surg 2007;134(5):1332-9.

33.Ye Lei; Haider Husnain Kh; Esa Wahidah Bte; Law Peter K; Zhang Wei; Su LiPing; Zhang Yong; Sim Eugene K W. Nonviral vector-based gene transfection of primary human skeletal myoblasts. Exp Biol Med 2007;232:1477-87.

34.Ye Lei; Haider Husnain Kh; Tan RuSan; Su LiPing; Law Peter K; Zhang Wei; Sim Eugene K W. Angiomyogenesis using liposome based vascular endothelial growth factor-165 transfection with skeletal myoblast for cardiac repair. Biomaterials 2008;29:2125-37.

35.Ye L; Lee K O; Su L P; Toh W C; Haider H K; Law P K; Zhang W; Chan S P; Sim E K W. Skeletal myoblast transplantation for attenuation of hyperglycaemia,

hyperinsulinaemia and glucose intolerance in a mouse model of type 2 diabetes mellitus. Diabetologia 2009;52:1925-34.

36.Ye Lei, Haider KhH, Esa WB, Su LP, Law PK, Zhang W, Lim YT, Poh KK, Sim EKW. Liposome-based vascular endothelial growth factor-165 transfection with skeletal myoblast for treatment of ischaemic limb disease. Journal of Cellular and Molecular Medicine 2010; 14: 323-336.

37.Law P K and Law DM. Human Myoblast Genome Therapies and Devices in Regenerative Medicine. Rec Pat Regen Med 2011; 1: 88-117.

38.Law PK, Li Y, Haider HKh, Lu P, Law DM, Sim EKW. Therapeutic angiomyogenesis using human non-viral transduced VEGF165- myoblasts. Open J Regen Med 1:1-9, 2012. 3.

39.Ye L, Su L-P, Pi WF, Law PK. Role of Thymosin β4 on skeletal myoblast migration, proliferation, and Survival. Rec Pat Regen Med 2012,2:146-155.

40.Ma J-H, Su L-P , Zhu J ,Law PK ,Lee K-O , Ye L, Wang ZZ. . Skeletal myoblast transplantation on gene expression profiles of insulin signaling pathway and mitochondrial biogenesis and function in skeletal muscle. Diabetes Res Clin Pr 102: 43-52, 2013.

41. Peter K. Law. Disease Prevention and Alleviation by Human Myoblast Transplantation. Open Journal of Regenerative Medicine, 2016, 5, 25-43.

42. Peter K. Law, Shi Jun Song , Ping Lu, Yong Gao, Mingzhang Ao, Hongdan Zhao, Liyun Bai 3 , Kang Guo 3 , Danlin M. Law. World's First Myoblast Treatment of Human Cancer Found Safe and Efficacious. Open Journal of Regenerative Medicine, 2017, 6, 1-16.

43. Weyland Cheng and Peter K. Law. Feedforward Coordinate Control of a Robotic Cell Injection Catheter. Cell Transplantation,2017, Vol. 26(8) 1319-1330.

44. Weyland Cheng and Peter K. Law. Conceptual Design and Procedure for an Autonomous Intramyocardial Injection Catheter. Cell Transplantation, Vol. 26, pp. 735–751, 2017.

Partial Patent Afer 2000

Worldwide Patents and Intellectual Property Assets

Granted and pending patents of Prof. Peter K. Law on myoblast compositions, applications and related medical devices.
Every issued PCT/EPO patent enables 65/25 patents to be issued in different TREATY COUNTRIES.- as represented by Dr. Klaus Hinkelmann, HINKELMANN & HUEBNER

Patent Number/ Published **Title** **Inventor**	**Definition**
U.S. 5,130,141/ 1992-07-14 **Compositions for and methods of treating muscle degeneration and weakness** LAW PETER K.	Broad pioneering patent in the field of myogenic cells and their use for repair of damaged muscle
WO9618303A1/ 1996-06-20 EP1407788A2/ 2004-04-14 DE P2116DE01 FR P2116FR01 GB P2116GB01 IE P2116IE01 AU748997/ 2002-09-26 CNZL95192528.8/ 2003-11-12 **Myoblast therapy for mammalian diseases** LAW PETER K.	Compositions and methods of treating mammalian diseases using myoblasts, and/or their physical, genetic, chemical derivatives. Myogenic cells that are normal, or genetically or phenotypically altered are cultured and transplanted into malfunctioning and/or degenerative tissues or organs to alleviate conditions that are hereditary, degenerative, debilitating, undesirable, and/or fatal. An automated cell processor for producing mammalian cells
US20020031501A1/ 2002-03-14 **Cardiomyocytes for heart muscles damaged in heart attacks** LAW PETER K.	Compositions and methods of treating mammalian diseases using myoblasts, and/or their physical, genetic, chemical derivatives. Myogenic cells that are normal, or genetically or phenotypically altered are cultured and transplanted into malfunctioning and/or degenerative tissues or organs to alleviate conditions that are hereditary, degenerative, debilitating, undesirable, and/or fatal

EP0898967 B1/ 1999-03-03 US7166279 B2/ 2007-01-23 DE69815230 T2/ 2004-05-06 IE0898967/ 2003-04-06 HK1016897/ 2004-05-07 ME226489/ 2005-02-28 **Myoblast transfer therapy for relieving pain and for treating behavioral and perceptive abnormalities** LAW PETER K	A method using myoblast transplant of continuously supplying in vivo a peptide such as an opioid peptide, substance P receptor, or substance P analog to treat intractable pain such as in heart attack and depression
Use of transduced myogenic cells **LAW PETER K**	German Part of EP Patent No. 898 967
WO03085092A2/2003-10-16 US20030232431A1/ 2003-12-18 WO03085092A3/2004-01-08 WO03085092B1/ 2004-02-19 US20050244384A1/ 2005-11-03 **Cellular transplantation for heart regeneration** LAW PETER K.	Producing cardiomyocytes capable of proliferating, useful for treating degenerative heart disease by injection, by fusion with myoblasts. Autologous, allogenic or xenogenic myoblasts obtained by culturing, particularly from satellite cells or other progenitor cells, are transplanted into tissue such as diseased heart tissue to form healthy repair tissue and reverse disease. Angiogenesis factors such as VEGF, migratory and scaffolding molecules may be transgenically expressed by the transplanted cell to augment the procedure
SI99846/ 2004-05-31 **Methods for producing cardiomyocytes capable of proliferation** LAW PETER K.	Compositions and methods of treating mammalian diseases using myoblasts, and/or their physical, genetic, chemical derivatives. Myogenic cells that are normal, or genetically or phenotypically altered are cultured and transplanted into malfunctioning and/or degenerative tissues or organs to alleviate conditions that are hereditary, degenerative, debilitating, undesirable, and/or fatal

US6261832/2001-07-17 **Automated cell processor** LAW PETER K	Treating mammalian diseases using myoblast(s) and their derivatives. An automated cell processor which enables the manufacture, at a single run, of unprecedented large quantities (greater than 100 billion) of normal or genotypically or phenotypically altered myogenic cells is disclosed
SI74036/2001-12-14 **Instrument for cell culture** LAW PETER K	An automated cell processor for producing mammalian cells
WO02/28470 A1/ 2002-04-11 SI95355/ 2005-05-31 EP1324802 B1/ 2006-11-15 AU2002211230/ 2007-0607 AU2002211230/ 2007-0607 AU2007202290/2012-02-16 AU2012200651/2015-05-14 US 60/231880 (pending) **Myogenic cell transfer catheter and method** LAW PETER K	Cardiovascular catheters and methods of their use for automatically injecting large quantities of myogenic cells for repairing and augmenting muscle and other tissues. The catheters are "smart" devices with built in injection timing that allows easy and more accurate injection of cells from inside a beating heart for its repair
WO2004/014302 A3/2004-02-19 CN03824045.9 (pending) U.S. Provisional Patent Appl. No. 60/402,050 **Mechanisms of myoblast transfer in treating heart failure** LAW PETER K.	Transduced myoblasts to treat heart muscle degeneration, baldness and male sexual impotency
CN1477190 A/ 2004-02-25 **Method and relative composition for controlling cell fusion** LAW PETER K	This invention teaches the induction of cell proliferation by introducing myoblast nuclei through controlled cell fusion.

WO/2004/030706/2004-4-15 **Bioactive implants** LAW PETER K MOTSENBOCKER Marvin A	Bioactive electrodes for implantation into existing muscles are provided that enhance the functioning of the muscles. The electrodes may be coated with myogenic cells and transplanted as a living package to provide a new and powerful tool for muscle repair or augmentation.
WO2005/020916 A2/ 2005-03-10 **Myoblast treatment of diseased or weakened organs** LAW PETER K	Normal or transduced cell therapies to treat and/or augment body structures such as the degenerative heart
US7341719 B1/ 2008-03-11 SI99279/ 2004-03-31 CN03101588.3 **Myoblast therapy for cosmetic treatment** LAW PETER K.	Compositions and methods of altering the cosmetic appearance of a body part using live cells such as normal myoblasts and their derivatives, to effect repair, or to augment the size, shape or the function of tissues or organs
WO017972/ 2004 CN03819963.7/ 2008-12-26 CN E038199637XS/2012-4-11 SI110581/2007-01-31 **Biologic skin repair and enhancement** LAW PETER K	This invention relates to the use of living cells such as myoblasts to repair and/or enhance skin
SI99846/ 2004-05-31 **Methods for producing cardiomyocytes capable of proliferation** LAW PETER K.	Compositions and methods of treating mammalian diseases using myoblasts, and/or their physical, genetic, chemical derivatives. Myogenic cells that are normal, or genetically or phenotypically altered are cultured and transplanted into malfunctioning and/or degenerative tissues or organs to alleviate conditions that are hereditary, degenerative, debilitating, undesirable, and/or fatal

US6261832/2001-07-17 **Automated cell processor** LAW PETER K	Treating mammalian diseases using myoblast(s) and their derivatives. An automated cell processor which enables the manufacture, at a single run, of unprecedented large quantities (greater than 100 billion) of normal or genotypically or phenotypically altered myogenic cells is disclosed
SI74036/2001-12-14 **Instrument for cell culture** LAW PETER K	An automated cell processor for producing mammalian cells
WO02/28470 A1/ 2002-04-11 SI95355/ 2005-05-31 EP1324802 B1/ 2006-11-15 AU2002211230/ 2007-0607 AU2007202290 US 60/231880 **Myogenic cell transfer catheter and method** LAW PETER K	Cardiovascular catheters and methods of their use for automatically injecting large quantities of myogenic cells for repairing and augmenting muscle and other tissues. The catheters are "smart" devices with built in injection timing that allows easy and more accurate injection of cells from inside a beating heart for its repair
WO03085092A2/2003-10-16 US20030232431A1/ 2003-12-18 WO03085092A3/2004-01-08 WO03085092B1/ 2004-02-19 US20050244384A1/ 2005-11-03 **Cellular transplantation for heart regeneration** LAW PETER K.	Producing cardiomyocytes capable of proliferating, useful for treating degenerative heart disease by injection, by fusion with myoblasts. Autologous, allogenic or xenogenic myoblasts obtained by culturing, particularly from satellite cells or other progenitor cells, are transplanted into tissue such as diseased heart tissue to form healthy repair tissue and reverse disease. Angiogenesis factors such as VEGF, migratory and scaffolding molecules may be transgenically expressed by the transplanted cell to augment the procedure
WO2005/020916 A2/ 2005-03-10 **Myoblast treatment of diseased or weakened organs** LAW PETER K.	Normal or transduced cell therapies to treat and/or augment body structures such as the degenerative heart

US7341719 B1/ 2008-03-11 SI99279/ 2004-03-31 CN03101588.3 **Myoblast therapy for cosmetic treatment** LAW PETER K	Compositions and methods of altering the cosmetic appearance of a body part using live cells such as normal myoblasts and their derivatives, to effect repair, or to augment the size, shape or the function of tissues or organs
WO017972/ 2004 CN03819963.7/ 2008-12-26 SI110581/2007-01-31 **Biologic skin repair and enhancement** LAW PETER K	This invention relates to the use of living cells such as myoblasts to repair and/or enhance skin
US13/968,982/2013-8-16 CN CN201310455357.4/2013-09-30 AU 2013231029/ 2013-9-17 EP 13 187 352.3/2013-10-4 **Disease prevention and alleviation by human myoblast transplantation** LAW PETER K	This invention relates to the composition and method of treating hereditary diseases using human cultured myoblasts, host serum and a suppressant such as cyclosporine for the prevention and/or treatment of heart diseases, type-II diabetes, muscular dystrophies, cancer and others.
PCT/IB2016/056459 EP17198789.4 **Composition comprising myoblasts for tumor growth inhibition and prevention of cancer cell metastasis by implantation** LAW PETER K	This invention relates to the composition of treating cancer using human cultured myoblasts, host serum and a suppressant such as cyclosporine.
PCT/IB2016/055617 **Autonomously controllable pull wire injection catheter, robotic system comprising said catheter and method for operating the same** LAW PETER K	The present invention relates to pull wire injection catheter comprising an outer catheter guide and an inner operating catheter, a robotic system comprising said pull wire injection catheter and a method for operating the same.

Licensing

Research Licenses

- Cell Therapy Research Foundation, Memphis, TN, USA, 1992-2004
- Samsung Cheil Hospital, Seoul, Korea, 1998-2001
- Yonsei University Rehab Institute of Muscular Diseases, Seoul, Korea,1998-2004
- Genesys Research Foundation, Sao Paolo, Brazil, 1998-2004
- Duke University, Durham, NC, USA, 2000-present
- Biosense Webster, Newark, NJ, USA, 2000-2001
- Arizona Heart Institute and Arizona Heart Hospital, Phoenix, AZ, USA, April 2001-2002
- National University of Singapore, Singapore, Singapore, 2001-present

Commercial Licenses

- Bioheart, Inc., Weston, FL, USA, May 2000 Conditional Exclusive License (Non-exclusive license with a first right of refusal) on Heart Muscle Regeneration and Angiogenesis

Conference Presentation After 2000

1. "Human Genome Therapy In Treating Heart Diseases". Advances in Cardiovascular Research – Clinical and Basic Sciences. Trinidad, West Indies, March 3-9, 2002.
2. "Myoblast Genome Therapy and the Regenerative Heart". Russian Academy of Medical Sciences. Moscow, Russia, June 12-19, 2002.
3. "Concomitant Angiogenesis of Infarcted Heart Using VEGF165-Myoblasts".
4. Cardiology/CT Surgery Conference. University of Arkansas for the Medical Sciences, August 21, 2002.
5. " Bioengineering the regenerative heart may provide treatment for heart failure." 13th Great Wall Meeting, Beijing, PRC, September 13-17, 2002.
6. "Bioengineering the Regenerative Heart May Provide Treatment for Heart Failure".
7. Transcather Cardiovascular Therapeutics (TCT), Washington, D.C., September 24-28, 2002.
8. "Human Genome Therapy and the Regenerative Heart". Second Sino-USA Symposium, Shanghai, October 25-29, 2002.
9. "Myoblast Genome Therapy and the Regenerative Heart". National Heart Center, University of Sao Paulo, Brazil, January 29-31, 2003.
10. "Allogeneic Myoblasts to Rejuvenate Degenerative Hearts: First-in-Man Study".
11. Transcather Cardiovascular Therapeutics (TCT), Washington, D.C., September 15-16, 2003.
12. " Myoblast Allografts in Human Heart Regeneration" The 15th Great Wall International Congress of Cardiology, ACC Symposium: Cardiology Update 2004.
13. " The Scientific Basis of Myoblast Transplantation" in Myoblast Transplant Comes of Age from Bench to Bedside and into Asia, Davos, Switzerland, June 24-26, 2005.
14. "Allografts Transplant First in Men" in Myoblast Transplant Comes of Age – from Bench to Bedside and into Asia, Davos, Switzerland, June 24-26, 2005.
15. "Cell Transplants in Singapore and China" in Myoblast Transplant Comes of Age – from Bench to Bedside and into Asia, Davos, Switzerland, June 24-26, 2005.
16. "Human Myoblast Genome Therapy HMGT Platform" The 17th Great Wall International Congress of Cardiology, ACC Heart Cell Therapy Symposium: Editor and Chairman Oct. 24, 2006.
17. "Human Myoblast Genome Therapy in Treating Muscular Dystrophies, Ischemic Cardiomyopathy, and Type II Diabetes", 100th Anniversary of Tongji Medical University, Shanghai, Oct. 28, 2006.
18. "Myoblast Genome Treatment for Ischemic Cardiomyopathy" The 18th Great Wall International Congress of Cardiology, ACC Symposium: Oct. 12, 2007.
19. "Angiomyogenesis using Myoblasts" ACC annual meeting, March 30, 2008.
20. "Human Myoblasts Provide Angiomyogenesis for Heart Patients" The 20th Great Wall International Congress of Cardiology, ACC Symposium: Oct. 12, 2009.

21. “The Role of Myoblasts in Myocardial Regeneration” Villa Maria Cotignola Hospital, Bologna, ITALY, April 19, 2010 .
22. “Human Myoblast Genome Therapy for Muscular Dystrophies” Besta Neurology Institute, Milan, ITALY, April 20, 2010.
23. “Heart Cell Therapy with Myoblasts” San Donato Hospital, Milan, ITALY, April 20, 2010.
24. “Heart Cell Therapy with Myoblasts” The Heart Institute Rome, ITALY, April 21, 2010.
25. “Angiomyogenesis of Infarcted Myocardium with Myoblasts.”Peking University Hospital, Beijing, CHINA. Nov. 1, 2010.
26. “The Uses of Myoblasts in Muscular Dystrophies, Heart Failure, Type II Diabetes, Aging and Cosmetics.” Tongji University School of Medicine, Wuhan, CHINA, June 16, 2011.
27. “The Use of Myoblasts in Treating Skin and Muscle Injuries Due to Trauma, Burns and Electricute." No. 3 Hospital of Wuhan, CHINA, July 18, 2011.